Literature DB >> 24248735

Prolonged low-dose thrombolysis in posterior circulation stroke.

C Hametner1, L Kellert, R Veltkamp, L Behrens, S Nagel, W Hacke, P Ringleb.   

Abstract

BACKGROUND: We aimed to investigate the feasibility, preliminary safety, and efficacy of prolonged low-dose intravenous thrombolysis in posterior circulation stroke patients with a thrombus lodged in the basilar artery who were ineligible for standard rtPA administration.
METHODS: We retrospectively analyzed consecutively collected patients in our stroke database who suffered from a basilar artery thrombosis and were treated with prolonged (>1 h), intravenous, low-dose (≤20 mg) rtPA between 01/2005 and 11/2012.
RESULTS: Patients included in this study (n = 14) were 68.5 years (IQR 55.5; 72.75) of age and presented with a median NIHSS of 2 (1; 5.25). Median time from symptom onset to treatment was 63 h (33; 141). A median dose of 5.21 μg/kg h (4.46; 6.25) rtPA was administered over 24 h (min 10; max 48). No patient experienced symptomatic intracerebral hemorrhage, one patient developed a spinal epidural hematoma, and two elderly patients were switched to comfort care and died. In eight patients (57%) a decrease in thrombus size or no thrombus at all was detected on control imaging. Nine patients (64%) had a favorable outcome (mRS 0-2) at day 90.
CONCLUSIONS: Prolonged low-dose thrombolysis with rtPA may be considered as individual treatment option in selected high-risk patients with basilar artery thrombosis. Presented data may lay the groundwork to further investigate safety and efficacy in a prospective trial.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24248735     DOI: 10.1007/s12028-013-9891-5

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  7 in total

Review 1.  Basilar artery occlusion.

Authors:  Heinrich P Mattle; Marcel Arnold; Perttu J Lindsberg; Wouter J Schonewille; Gerhard Schroth
Journal:  Lancet Neurol       Date:  2011-11       Impact factor: 44.182

2.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

3.  Intravenous thrombolysis of basilar artery occlusion: predictors of recanalization and outcome.

Authors:  Tiina Sairanen; Daniel Strbian; Lauri Soinne; Heli Silvennoinen; Oili Salonen; Ville Artto; Ilkka Koskela; Olli Häppölä; Markku Kaste; Perttu J Lindsberg
Journal:  Stroke       Date:  2011-07-07       Impact factor: 7.914

4.  Prolonged low-dose intravenous thrombolysis in a stroke patient with distal basilar thrombus.

Authors:  Roland Veltkamp; Christian Jacobi; Bodo Kress; Werner Hacke
Journal:  Stroke       Date:  2005-12-08       Impact factor: 7.914

5.  Thrombolysis of basilar artery occlusion: impact of baseline ischemia and time.

Authors:  Daniel Strbian; Tiina Sairanen; Heli Silvennoinen; Oili Salonen; Markku Kaste; Perttu J Lindsberg
Journal:  Ann Neurol       Date:  2013-07-08       Impact factor: 10.422

6.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

7.  Time is brain(stem) in basilar artery occlusion.

Authors:  Mervyn D I Vergouwen; Ale Algra; Thomas Pfefferkorn; Christian Weimar; Christina M Rueckert; Vincent Thijs; L Jaap Kappelle; Wouter J Schonewille
Journal:  Stroke       Date:  2012-09-18       Impact factor: 7.914

  7 in total
  1 in total

1.  Case report: Combined acute revascularization in early bilateral carotid stent occlusion.

Authors:  David Černík; Robert Bartoš; Jarmila Neradová; Nicol Frenštátská; Filip Cihlář; Štěpánka Brušáková; Martin Sameš
Journal:  Front Neurol       Date:  2022-09-16       Impact factor: 4.086

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.